Commercial Hiring Timeline for a Gene and Cell Therapy Launch
By Travis Sjursen, Founder, Permanent Solutions Group
Gene and cell therapy launches break the standard pharma commercial playbook, and the hiring timeline has to break with it. One-time treatments, seven-figure price tags, qualified treatment centers instead of broad prescriber bases, outcomes-based contracts, and complex logistics all mean your commercial build starts earlier and looks different from a conventional specialty launch. Here's the timeline I walk clients through.
24+ months before approval: the strategist
Your first hire, a CCO or VP of Commercial, needs prior advanced-therapy exposure or the demonstrated ability to build unconventional models. The core strategic questions in gene therapy are commercial ones: center-of-excellence footprint, pricing and value demonstration for a one-time cure, payer risk-sharing structures. Someone has to own those answers while the BLA is still being assembled.
18 to 24 months out: market access and value
If access matters in specialty pharma, it's existential in cell and gene. A single-administration therapy priced above a million dollars gets exactly one chance at a payer value story. This hire builds health economics evidence, outcomes-based agreement frameworks, and government-payer strategy long before approval. In my experience this is the scarcest talent pool in the entire sector; the people who've actually negotiated outcomes-based deals for approved gene therapies number in the dozens, and everyone wants them.
15 to 18 months out: treatment center strategy
Unique to advanced therapies: someone has to own site qualification, onboarding, and activation. Whether it's titled VP of Site Strategy, Center Engagement, or folded into a broader commercial ops role, treatment centers are your entire distribution channel. A launch with 30 activated centers and a launch with 8 are different companies.
12 to 15 months out: marketing and patient services
Marketing in gene therapy is heavily disease-education and referral-pathway work: getting diagnosing physicians to identify patients and refer them into qualified centers. Patient services carries more weight than in any other launch type, since families navigating a one-time therapy need case management from first referral through post-infusion follow-up. Hire the patient services lead early enough to design the hub before it's needed, not while it's needed.
6 to 12 months out: field teams, sized honestly
Field forces in cell and gene are small and senior: key account roles covering treatment centers and referral networks, not territory reps carrying scripts. Teams of 10 to 25 are common. What you're paying for is clinical credibility and account management depth, so expect above-market comp per head and resist the urge to scale count over quality.
The compounding mistake
Every one of these searches draws from a shallow pool. Genuine advanced-therapy commercial experience is held by a few hundred people, most currently employed and heavily recruited. Starting a search 60 days later than you should doesn't cost you 60 days; it can cost you the candidate, because in pools this small the second-best option is a real step down. Timeline discipline is the whole game.
Frequently asked questions
- When should a gene therapy company hire its first commercial leader?
- At least 24 months before anticipated approval, and earlier if payer strategy or center footprint questions are already shaping the program.
- How is a cell and gene therapy sales force different?
- Smaller, more senior, and account-based. Reps manage qualified treatment centers and referral pathways rather than high-volume prescriber territories.
- What commercial roles are hardest to fill in cell and gene therapy?
- Market access leaders with real outcomes-based contracting experience, followed by treatment-center strategy roles. Both pools are measured in dozens, not thousands.